Edison Issues Update on Quantum Genomics (ALQGC)

Wednesday, April 5, 2017 General News
Email Print This Page Comment
Font : A-A+

LONDON, April 5, 2017 /PRNewswire/ --

Quantum Genomics reported its yearly results, which highlighted the significant

progress the company has made towards the commercialisation of its product, QGC001, for treatment of hypertension (HT) and heart failure (HF). In 2016, the company both completed a 34-person Phase II HT trial (results expected June
2017
) and initiated a 75-person European Phase II trial examining the drug for HF (results early 2018). The company is also set up to initiate a US Phase II for HT in H217.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

We have increased our valuation of Quantum Genomics to €180m or €20.60 per share from €172m or €20.51 per share. This is due to advancing our NPVs, offset by lower net cash and moving up some R&D spending. We expect to update our valuation following the release of results in June 2017 from the previously completed Phase IIa HT trial.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

http://www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

     LinkedIn: https://www.linkedin.com/company/edison-investment-research   Twitter: http://www.twitter.com/Edison_Inv_Res   YouTube: http://www.youtube.com/edisonitv

London +44-(0)20-3077-5700 280 High Holborn London, WC1V 7EE United Kingdom

SOURCE Edison Investment Research



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook